LifeSci Capital Initiates Coverage of Kamada

Lead Product Glassia is Approved in Large and Growing AAT Deficiency Market; Report Available here: http://www.lifescicapital.com/equity-research/kamada/

NEW YORK, NY / ACCESSWIRE / September 12, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Kamada (NasdaqGS: KMDA), a revenue generating biopharmaceutical company that develops and commercializes plasma-derived protein therapeutic products. The Company’s lead product and main revenue driver is Glassia, an alpha-1 antitrypsin (AAT) replacement therapy used to treat AAT deficiency. Glassia revenues have been consistent over the past several years due to a US commercialization agreement with Baxalta, now Shire (NasdaqGS: SHPG), though the Company has indicated a substantial uptick in demand for this product that is expected to increase revenues of their proprietary product line significantly in 2017.

Kamada has a robust pipeline largely based on their AAT therapy, which includes a novel inhaled AAT formulation. The company recently reported positive data from a Phase II clinical trial with inhaled AAT for AAT deficiency, which met its primary endpoint and demonstrated that the inhaled formulation adequately delivered antigenic AAT to the lungs. The Company also has a steady revenue stream derived from 9 pharmaceutical products and the distribution of 10 products.

Of the estimated 100,000 individuals with AAT deficiency in the US, only approximately 6,000 have been diagnosed and are seeking treatment. One of the main drivers behind Glassia prescription growth is an increase in the overall pool of diagnosed, treatment-seeking AAT deficient individuals. With the recent development of blood and genotyping tests, patients are able to receive testing for AAT deficiency via drug companies and patient advocacy groups. Based on the advances in awareness and testing, Glassia’s differentiated convenience profile, and current prescription trends, we project a 5 to 10-fold increase in total Glassia prescriptions by 2024.

In a 38 page Initiation Report, LifeSci Capital describes the Company’s treatment for AAT deficiency, how the product is differentiated from currently available therapies, and the large market opportunity for AAT augmentation therapies in AAT deficiency as well as other indications.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Kamada as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 445156